In about >95% of the APL cases, a chimeric fusion gene that drives the pathogenesis originates in the chromosome translocation 15q24 and PML-RARα is a successful target for therapy using all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) (1). This evidence concerns the gene PML and acute promyelocytic leukemia.